BioStock: Alligator gearing up for new milestones with mitazalimab

The 52 per cent Objective Response Rate measured with mitazalimab in the phase II OPTIMIZE-1 trial has given Alligator Bioscience positive momentum for continued advancements. The results have put the company on a path towards discussions with regulators for accelerated development of the CD40 agonist. The company now seeks to raise approximately 199 MSEK in a rights issue to deliver its next key value inflection points.

Read the article at biostock.se:

Alligator gearing up for new milestones with mitazalimab - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/